Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the german myeloma study group DSMM
peer-reviewed
Erstveröffentlichung
2021-03-16Authors
Bachmann, Friederike
Schreder, Martin
Engelhardt, Monika
Langer, Christian
Wolleschak, Denise
Wissenschaftlicher Artikel
Published in
Cancers ; 13 (2021), 6. - Art.-Nr. 1322. - eISSN 2072-6694
Link to original publication
https://dx.doi.org/10.3390/cancers13061322Institutions
Klinikum Schwäbisch Gmünd StauferklinikUKU. Klinik für Innere Medizin III
Document version
published version (publisher's PDF)Abstract
Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex; VCD) or btz, lenalidomide (len), and dex (VRd) or len, adriamycin, and dex (RAD). The minimum required estimated glomerular filtration rate (eGFR) was >30 mL/min. We analyzed the percent change of the renal function using the International Myeloma Working Group (IMWG) criteria and Kidney Disease: Improving Global Outcomes (KDIGO)-defined categories. Results: Seven hundred and seventy-two patients were eligible. Three hundred and fifty-six received VCD, 214 VRd, and 202 RAD. VCD patients had the best baseline eGFR. The proportion of pts with eGFR <45 mL/min decreased from 7.3% at baseline to 1.9% PInd (p < 0.0001). Thirty-seven point one percent of VCD versus 49% of VRd patients had a decrease of GFR (p = 0.0872). IMWG-defined “renal complete response (CRrenal)” was achieved in 17/25 (68%) pts after VCD, 12/19 (63%) after RAD, and 14/27 (52%) after VRd (p = 0.4747). Conclusions: Analyzing a large and representative newly diagnosed myeloma (NDMM) group, we found no difference in CRrenal that occurred independently from the myeloma response across the three regimens. A trend towards deterioration of the renal function with VRd versus VCD may be explained by a better pretreatment “renal fitness” in the latter group.
Subject headings
[GND]: Niereninsuffizienz | Plasmozytom[MeSH]: Multiple myeloma | Renal insufficiency | Bortezomib | Lenalidomide
[Free subject headings]: renal failure | kidney | induction regimen
[DDC subject group]: DDC 610 / Medicine & health
Metadata
Show full item recordDOI & citation
Please use this identifier to cite or link to this item: http://dx.doi.org/10.18725/OPARU-45061
Bachmann, Friederike et al. (2022): Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the german myeloma study group DSMM. Open Access Repositorium der Universität Ulm und Technischen Hochschule Ulm. http://dx.doi.org/10.18725/OPARU-45061
Citation formatter >